TMEM175 screening using a multi-platform approach – including electrophysiology and fluorescence-based assays – enables comprehensive profiling and characterization. Sygnature Discovery supports ion channel drug discovery through flexible, high-quality TMEM175 assay capabilities.
Introduction
TMEM175 is a novel, constitutively active ion channel involved in the regulation of lysosomal pH, lysosomal Δψ and autophagy. TMEM175’s significance lies not only in its physiological role but also in its therapeutic promise. Dysfunction of TMEM175 has been associated with lysosomal storage disorders and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. As such, understanding TMEM175’s role in health and disease may provide opportunities for therapeutic interventions targeting these conditions. Sygnature Discovery stands at the forefront of TMEM175 research, offering an array of specialized services and cutting-edge capabilities to understand this target’s therapeutic potential.
Supporting Your Research
Despite TMEM175’s emerging relevance in neurodegenerative disease biology, the lack of selective pharmacological tools has historically limited research into its functional mechanisms and therapeutic potential. At Sygnature Discovery, we address this challenge with a comprehensive, multi-platform approach designed to empower drug discovery teams to explore TMEM175 with precision and confidence.
We offer a catalogue of validated cell lines and electrophysiology assays tailored for TMEM175, including:
-
Wild-type and disease-relevant TMEM175 variants, covering both loss-of-function (LoF) and gain-of-function (GoF)
-
Key species orthologs
-
High-throughput screening cascades that quantitatively assess compound effects across TMEM175 variants using EC₅₀/IC₅₀ curves
-
Solid-supported membrane (SSM) electrophysiology, ideal for interrogating TMEM175 activity in lysosomal membranes
-
Orthogonal validation options, combining automated patch clamp and SSM electrophysiology to confirm modulator effects and mechanism of action
By providing access to a spectrum of TMEM175 reagents and assay formats, Sygnature Discovery’s platform enables you to:
-
Profile variant-specific pharmacological responses
-
Discover novel TMEM175 modulators with therapeutic potential
-
Better understand the lysosomal pH regulation and its therapeutic disruption
With over 20 years experience supporting ion channel drug discovery, we offer the scientific expertise and platform flexibility needed to support TMEM175 drug discovery programs.
